Table of contents
- Human Cytomegalovirus Infection Downregulates Vitamin-D Receptor in Mammalian Cells
- Material and Methods
- Vitamin D metabolites do not inhibit CMV replication
- 14 papers cited this study as of Aug 2021
- CMV on the web
- CMV and VITAMIN D on the web
J Steroid Biochem Mol Biol. 2017 January ; 165(Pt B ): 356-362. doi:10.1016/j.jsbmb.2016.08.002.
Franz JJ Rieder1, Charlotte Groschel2, Marie-Theres Kastner1, Karin Kosulin3, Johannes Laengle4, Rene Zadnikar5, Rodrig Marculescu5, Martina Schneider1, Thomas Lion3-6, Michael Bergmann4, Eniko Kallay2, and Christoph Steininger1, email@example.com.
1Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria
2Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
3Children’s Cancer Research Institute, Vienna, Austria
4Department of Surgery, Medical University of Vienna, Vienna, Austria
5Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
6Department of Pediatrics, Medical University of Vienna, Vienna, Austria
The Cytomegalovirus quickly downregulates the Vitamin D Receptor by 8X in the lab
Human tissue compensates by increasing active Vitamin D production by 9.7 X
These changes have not been observed in other viruses.
Vitamin D (VD) is essential for the human body and involved in a wide variety of critical physiological processes including bone, muscle, and cardiovascular health, as well as innate immunity and antimicrobial responses. Here, we elucidated the significance of the VD system in cytomegalovirus (CMV) infection, which is one of the most common opportunistic infections in immunocompromised or -suppressed patients. We found that expression of vitamin D receptor (VDR) was downregulated in CMV-infected cells within 12 hours [hrs] post infection [p.i.] to 12 % relative to VDR expression in mock-infected fibroblasts and did not recover during the CMV replication cycle of 96 hrs. None of the biologically active metabolites of VD, cholecalciferol, calcidiol, or calcitriol, inhibit CMV replication significantly in human fibroblasts. In a feedback loop, expression of CYP24A1 dropped to 3 % by 12 hrs p.i. and expression of CYP27B1 increased gradually during the replication cycle of CMV to 970 % probably as a consequence of VDR inhibition. VDR expression was not downregulated during influenza virus or adenovirus replication. The potent synthetic vitamin D analog EB-1089 was not able to inhibit CMV replication or antagonize its effect on VDR expression. Only CMV replication, and none of the other viral pathogens evaluated, inhibited the vitamin D system in vitro. In view of the pleiotropism of VDR, CMV-mediated downregulation may have far-reaching virological, immunological, and clinical implications and thus warrant further evaluations in vitro and in vivo.
Download the PDF from VitaminDWiki
Cytomegalovirus (CMV) infection is one of the clinically most significant infectious complications of solid-organ transplantation (reviewed in ). CMV infection, defined as a significant rise in the titer of CMV-specific antibodies, occurs in 44 % to 85 % of kidney, heart, and liver transplant recipients - primarily in the first 3 months post transplantation, when immunosuppression is most intense. CMV disease manifests in transplant recipients primarily in the organ transplanted with the risk of consecutive dissemination and impairment of other organs such as the central-nervous system, eye, and urogenital- or gastrointestinal tract. Moreover, active CMV infection is a significant independent predictor of acute graft rejection and occurrence of opportunistic infections [1,2].
Graft dysfunction and rejection are associated with vitamin D (VD) deficiency. In patients with end-stage organ failure awaiting transplant, VD insufficiency and deficiency are extremely common. Insufficient levels of vitamin D metabolites (25-hydroxyvitamin D [25(OH)D3] and 1,25-hydroxyvitaminD [1a,25(OH)2D3] have been reported for patients with terminal congestive heart failure , pulmonary disease , liver failure , and chronic kidney disease . International agreement upon the cut-offs for vitamin D insufficiency is still pending, but optimallevel of 25(OH)D3 have been widely accepted to range between 50 and 80 nM for musculoskeletal health . Observations in animal studies suggest that administration of 1a，25(OH)2D3 (calcitriol)，which is the active metabolite of VD, can prevent acute allograft rejection following liver , kidney , and heart  transplantation. These observations could be validated in kidney transplant recipients, where calcitriol supplementation was associated with fewer episodes of acute cellular rejection , reduced glucocorticoid requirements , and decreased expression of co-stimulatory and human leukocyte antigen - DR (HLA-DR) molecules that may mediate allograft rejection .
The VD system is vital for the human organism and is involved in a wide variety of critical physiological processes. Its major biological function is the regulation of plasma calcium and phosphate homeostasis and bone remodeling, mostly by controlling resorption and metabolism of dietary calcium. VD system regulates also a diversity of other biological processes and hence, VD deficiency may increase the risk for multiple cardiovascular, inflammatory, autoimmune and malignant diseases (reviewed in ).
Conversion of cholecalciferol, the biologically inactive precursor of vitamin D, to its biologically active metabolite 1a,25(OH)2D3 (calcitriol) requires two hydroxylation steps that are accomplished by the 25-hydroxylases (CYP27A1 and CYP2R1) and by the 1a- hydroxylase (CYP27B1) . After binding calcitriol, the vitamin D receptor (VDR) is imported into the nucleus and binds to vitamin D response elements (VDRE) on the promoter region of target genes as a heterodimer with the retinoid-X receptor [16,17]. Consecutively, VDR regulates transcription of 200 to 1250 genes in a cell- and tissue-dependent manner (reviewed in ). In parallel, calcitriol induces in a negative feedback loop its rapid degradation by upregulation of the 24-hydroxylase (CYP24A1) and suppression of CYP27B1 expression for a tight control of 1a,25(OH)2D3 levels 
Calcitriol is involved also in the regulation of the innate immunity. Calcitriol influences the priming of the immune system, migration of immune cells, induction of regulatory T-cells, and production of antibacterial peptides [19,20]. For example, activation of the Toll-like receptor 2 (TLR2) upregulates transcription of VDR gene in human macrophages . As a consequence, hundreds of genes are activated , including those coding for the antimicrobial peptide cathelicidin [21,22].
Calcitriol may also have direct antimicrobial effects. It triggers autophagy in macrophages and thereby inhibits replication of human immunodeficiency virus-1 (HIV-1) [23,24]. Hepatitis C virus (HCV) infected children treated with cholecalciferol and antiviral drugs have an earlier sustained virological response than those receiving only antiviral drugs . Low vitamin D levels are associated with treatment failure among HCV-infected patients receiving pegylated-interferon and ribavirin . Moreover, vitamin D was also found to be protective against bacterial infections such as Chlamydia spp.and mycobacterial infections [27-29].
The aim of the present study was to assess a possible antiviral effect of vitamin D and its metabolites in CMV infection. Systematic screening of solid-organ transplant patients for vitamin D deficiency and, if necessary, supplementation would be a non-toxic and very likely highly efficient measure to reduce the risk of CMV disease significantly. Surprisingly, vitamin D was unable to inhibit CMV replication; in contrast, CMV, but not other human viruses evaluated, affected significantly the vitamin D system.
For the propagation of CMV, human foreskin fibroblasts (HFF, kindly provided by Dr. Thomas Mertens, University Medical Center Ulm, Germany) were cultured in Dulbecco's modified eagle medium (DMEM GlutaMAX, Thermo Fischer Scientific, Waltham, MA, USA) supplemented with 10 % fetal calf serum (FCS) and Antibiotic-Antimycotic mix (Thermo Fischer Scientific, Waltham, MA, USA). HFF were then trypsinized, seeded to approximately 80 % confluence and subsequently infected with CMV (laboratory strain AD169) at a multiplicity of infection (MOI) of 0.01. The viral suspension was replaced by culture medium after 90 minutes. Virus culture was harvested after a total cytopathic effect (CPE) was visible. Cell debris was removed by centrifugation at 3000 g for 20 minutes and the virus supernatant was stored in DMEM supplemented with 20 % FCS at -80 °C. MOI was measured with use of a plaque assay as described previously . The human adenovirus type 2 (ATCC) was propagated in the human alveolar adenocarcinoma epithelial cell line A549 grown in DMEM culture medium supplemented with 5 % FCS and 1 % penicillin/streptomycin mix (Thermo Fischer Scientific, Waltham, MA, USA). Upon observation of a CPE, the virus was harvested by performing three freezing and thawing cycles followed by centrifugation at 4000 g for 10 minutes. Aliquots of the supernatant were used for subsequent experiments. For the propagation of influenza virus, A549 cells were maintained in Dulbecco's modified eagle medium/nutrient mixture F-12 (DMEM/F-12; Thermo Fischer Scientific, Waltham, MA, USA) supplemented with 10 % heat-inactivated FCS (Linaris, Dossenheim, Germany). African green monkey kidney Vero cells (ECACC, 88020401) were cultivated in OptiPRO medium (Thermo Fischer Scientific, Waltham, MA, USA). The influenza A/PuertoRico/8/34 virus (H1N1) and influenza A/Aichi/2/68 virus (H3N2) were used in the present study. Influenza A virus propagation was done in Vero cells in the presence of 5 ug/ml trypsin (Sigma Aldrich, St. Louis, Missouri, USA) after infection with a MOI of 0.1. Virus titer concentrations were assessed by plaque assays on Vero cells. All cell lines were grown in a humidified 5 % CO2 atmosphere at 37 °C.
For analysis of VDR and VD-associated genes, HFF cells were seeded to reach 80 % confluence at time of infection, mock- or CMV-infected (MOI=5) and harvested 1, 12, 24, 36, 72 and 96 hrs p.i. A549 cells were used at a cell density of 6 x 105 cells per well in 6- well plates, mock- or adenovirus-infected (MOI=10) and harvested 1, 12 and 24 hrs p.i. For influenza A viruses, 1 x 106 A549 cells per well were seeded on 6-well plates, infected with the two different virus strains (MOI=5) or mock-infected and harvested 1, 12, 24, 36 and 48 hrs p.i.
For western blot analysis, HFF were seeded to reach 80 % confluence and infected with CMV AD169 with a MOI of 3. Final concentrations of calcitriol and EB-1089 were maintained constant during all phases of the experiment. Cells were harvested at time points p.i. indicated for each experiment, respectively and lysed by resuspension in lysis buffer (TBS, 1 % NP-40) and sonication.
CMV plaque assays were performed as described previously . Cholecalciferol (C9756, Sigma Aldrich, St. Louis, Missouri, USA), calcidiol, calcitriol (cat. no. H4014 & D1530, respectively, Sigma Aldrich, St. Louis, Missouri, USA), and Ganciclovir (cat. no. 345700, Merck Millipore, Billerica, MA, USA) were used at two-fold dilutions starting with a concentration of 100 uM, respectively. For the evaluation of the vitamin D agonist EB-1089 (Seocalcitol EB-1089, Santa Cruz Biotechnology, Dallas, Texas, USA) two-fold dilutions starting with a concentration of 200 nM were used and supplemented with calcitriol at a constant concentration of 1 nM; Ganciclovir was used as control starting with 200 um. The cutoff of the antiviral effectivity of the compounds was defined by the widely used IC50 (half maximal inhibitory concentration).
Protein concentration of lysates was measured with use of a commercially available BCA- assay according to the manufacturer's recommendations (Thermo Fisher Scientific,Waltham, MA, USA). Cell lysates were diluted for western blot analysis in 5x reducing sample buffer (300 mM Tris, pH 6.8, 50 % glycerol, 0.05 % Bromophenol blue, 10 % SDS and 10 % 2-Mercaptoethanol) and boiled at 99°C for 5 minutes. Subsequently, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed with use of 8 % gels. Membranes were blocked with StartingBlock T20 (PBS) Blocking Buffer (ThermoFisher Scientific, Waltham, MA, USA), and evaluated with use of the following primary antibodies: anti-VDR (SAB4503071, Sigma Aldrich, St. Louis, Missouri, USA), anti-IE1/ pp72 (sc-69834, Santa Cruz Biotechnology, Dallas, Texas, USA), and anti-beta-tubulin HRP (#ab21058, abcam, Cambridge, UK). Secondary HRP-labeled antibodies to target anti-VDR and anti-IE1 primary antibodies were obtained from Jackson Immuno Research (West Grove, PA, USA). SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA) was used to visualize the blots. Membranes were stripped with Restore PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific, Waltham, MA, USA) for reprobing. Band signal intensity on western blots was measured with use of a ChemiDoc Imaging System (Biorad Inc., Hercules, CA, USA) and analyzed using the Image Lab 5.0 software (Biorad Inc., Hercules, CA, USA).
RNA extraction was performed on a QIAcube fully automatic sample processor using the RNeasy Mini Kit with the "Customized protocol for purification of total RNA from animal cells (with QIAshredder)" (Qiagen, Venlo, Netherlands). The elution volume was 50 uL. RNA concentration was determined with a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized from 3 ug RNA with the "High- Capacity cDNA Reverse Transcription Kit with RNase Inhibitor" (Thermo Fisher Scientific, Waltham, MA, USA) in a 60 ul reaction volume according to the manufacturer's protocol.
Quantitative real time RT-PCR (qRT-PCR) was performed on the ABI Step One Plus RealTime PCR System (Thermo Fisher Scientific, Waltham, MA, USA) in duplicates using Power SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). PCR cycling conditions were 10 minutes (min) at 95 °C, followed by 40 cycles of 15 seconds (s) at 95 °C and 60 s at 60 °C. Beta-2-microglobulin (h/32M) was used as housekeeping gene. Primers for VDR, CYP24A1, CYP27B1 and h/32Mha\e been described previously [31-33]. The AACt method was applied to calculate fold changes in gene expression, relative to housekeeping genes and normalized to a commercially available total RNA calibrator (Clontech, Mountain View, CA, USA) according to Livak et al .
To evaluate the impact of CMV infection on the vitamin D system, we assessed the relative mRNA expression of VDR, the 1a-hydroxylase (CYP27B1) and the 24-hydroxylase (CYP24A1). Quantification of VDR-specific mRNA in CMV-infected human foreskin fibroblasts (HFF) revealed that VDR expression was downregulated to 12 % within 12 hours (hrs) post infection (p.i.) relative to the VDR expression in mock-infected HFF (Fig 1). After 12 hrs p.i., VDR expression recovered partially but maximum relative values did not exceed 41 % during the 96 hrs of observation, which is the equivalent time for one replication cycle of the CMV strain AD169 used. In parallel, relative gene expression of CYP27B1 and CYP24A1 were quantified to evaluate feedback loops associated with VDR expression. Relative expression of CYP24A1dropped in CMV infected HFF to 3 % relative to mock- infected HFF 12 hrs p.i. and did not recover substantially during the observation period of 96 hrs p.i. In contrast, expression of CYP27B1 increased gradually during the replication cycle of CMV relative to that measured in mock-infected HFF from 190 % at 12 hrs p.i. to 970 % at 96 hrs p.i. (Fig 1).
To investigate whether vitamin D or its metabolites inhibit the replication of CMV, we performed plaque reduction assays in HFF treated with decreasing concentrations of cholecalciferol, calcidiol, or calcitriol. In these experiments, neither the biologically most active form of vitamin D, calcitriol, nor its precursors cholecalciferol or calcidiol inhibited the replication of CMV significantly despite supra-physiological concentrations (Fig 2). We observed a minor inhibition of viral replication in the range of 0-30 %. However, this inhibition did not exceed the IC50 (half maximum inhibitory concentration). Of note, cholecalciferol at the maximum concentration of 100 uM induced a pronounced cytopathic effect (CPE) in the HFF cells and the antiviral effect at this high concentration was therefore not evaluated. A reduced viability of cells reduces the permissiveness for viral replication and would thereby bias results. The antiviral drug ganciclovir, used as control, had a strong antiviral effect causing 100 % inhibition of viral replication down to a final concentration of 6.25 uM.
Expression of mRNA may not correlate with protein levels because of occasionally discordant regulation [34,35]. To examine VDR gene expression at the protein level, HFF were CMV- or mock-infected and VDR protein levels were evaluated by Western blotting. The VDR-specific signal measured in lysate from mock-infected, calcitriol-treated HFF was stronger 24 and 72 hrs p.i. than at 0 hrs p.i., which indicates calcitriol-mediated upregulation of VDR (Fig 3A). The VDR-specific signal measured in CMV-infected, calcitriol-treated HFF was clearly weaker than in the corresponding mock-infected samples collected at the same time points 24 and 72 hrs p.i. To confirm presence of viral infection in the HFF, all samples were also probed with a mAb specific for the immediate early antigen-1 (IE1/pp72) of CMV, which is detectable within one hour p.i.
To evaluate whether the downregulation of VDR during CMV replication may be antagonized, CMV- or mock-infected HFF were treated in parallel with EB-1089, a vitamin D analog that has been used successfully to counteract the VDR gene downregulation induced by HIV replication [36,37] (Fig 3B). In these experiments, signals obtained when probing lysates from CMV- and mock-infected HFF were identical to those measured without EB-1089, which indicates that EB-1089 was not able to counteract VDR protein downregulation during CMV replication (Fig 3B). To evaluate a potential antiviral effect of EB-1089, plaque reduction assays were carried out in HFF treated with decreasing concentrations of the compound (Fig 4). In contrast to Ganciclovir, EB-1089 had only a marginal inhibitory effect (<10 %) on CMV replication compared with the mock-treated HFF - even at the highest concentrations used (200 nM).
To evaluate whether the observed down-regulation of the VDR gene during CMV replication is a common phenomenon occurring in association with viral infections, we evaluated VDR gene expression in mammalian cells infected with the influenza A/PuertoRico/8/34 virus (H1N1), influenza A/Aichi/2/68 virus (H3N2), or with one human adenovirus type 2 strain (HAdV2). Cells were harvested at 1, 12 and 24 hrs for adenovirus and 1, 12, 24, 36 and 48 hrs p.i. for influenza A viruses. These harvesting time points were chosen because of the shorter replication cycles of influenza A and adenoviruses in cell culture compared with CMV, and because the CPE occurring after 24 and 48 hrs; respectively. VDR mRNA expression of adenovirus-infected samples relative to mock-infected control peaked initially (one hour p.i.) at 160 % but decreased thereafter to 82 % and 95 % at 12 and 24 hrs p.i., respectively. Of note, this high relative expression is based on an outliner in the replicates with ~220 % in contrast to the corresponding replicate which showed almost perfectly 100 % (99.88 %). Relative VDR expression of influenza A virus infected samples increased with ongoing virus infection after an initial drop. Maximum levels were reached 96 hrs p.i. influenza A(H1N1) virus increased VDR mRNA levels by 600% while A(H3N2) by 1058 % relative to the mock-infected controls (Fig 5).
In the past few years, there has been increasing interest in the complex interplay between vitamin D and infectious pathogens (for a review see 38. Vitamin D supplementation is beneficial for patients with HIV, hepatitis C virus, Chlamydia spp.or mycobacterial infection [23-29]. A significant reduction in the risk of CMV infection and disease by vitamin D supplementation would be highly attractive because of a high therapeutic index of vitamin D, the ease of application (oral solutions), and added benefits such as improved musculoskeletal health. Contrary to expectation, we found that CMV infection interferes with the vitamin D system of mammalian cells. CMV infection downregulated VDR expression and this downregulation was specific for CMV and was not observed for other, common human viruses. This observation may have far-reaching virological, immunological, and clinical implications.
CMV is one of the most significant viral pathogens in immunocompromised or - suppressed patients. In solid-organ and bone-marrow transplant patients, CMV is the most common opportunistic virus infection with an incidence of up to 85 % and is associated with significant morbidity and mortality . HIV-infected patients are at high risk for CMV disease during periods of intense immunodeficiency . Treatment of patients with the monoclonal antibody Alemtuzumab for chronic lymphocytic leukaemia is accompanied with CMV reactivation and disease in up to 66 % of patients . Moreover, CMV infection is the leading cause of congenital viral infection in Western countries with an overall birth prevalence of 0.64 % . In view of the significant impact of CMV infection on human health, better prophylactic and therapeutic options are urgently needed. We found, however, in vitroevidence that CMV replication is not inhibited by calcitriol, the biologically active vitamin D metabolite, nor by cholecalciferol or calcidiol, even at supra-physiological concentrations. Evidence on the risk of CMV infection and disease in association with vitamin D deficiency is limited so far to the study of only one cohort of kidney transplant patients . In concordance with our findings, vitamin D deficiency was not associated with CMV disease . Hence, vitamin D supplementation may not affect significantly CMV replication in vivo.
We found, a rapid, pronounced, and sustained downregulation of the VDR gene during CMV replication. We validated the gene expression data also on protein level and demonstrated a significant decrease in VDR protein levels during CMV replication. VDR is ubiquitously expressed in the human body including cells of the pancreas, kidneys, intestine, bones and cartilage, epithelium, endocrine glands and testes, as well as in T-cells, monocytes and dendritic cells [42,43]. As VDR participates in multiple signaling pathways, low VDR levels would not only compromise vitamin D signaling but would also derail the homeostasis of other signaling pathways. In VDR knock-out mice the risk for severe musculo-skeletal disorders , dysbiosis of the intestinal microbiome , defective autophagy , improper wound healing , or bacterial, or mycobacterial infections  is significantly increased. In kidney, or liver transplant patients, VDR polymorphisms are associated with increased risk of CMV disease [48,49]. The present observation that CMV replication downregulates VDR expression warrants further clinical trials to elucidate the complex interference of CMV with the vitamin D system in vivo.
Interference of CMV with vitamin D signalling may be very different compared with that of other intracellular pathogens. HIV for example, infects kidney cells, hijacks the cellular machinery to provide suitable host factors for viral replication, and thereby, downregulates VDR gene expression and triggers HIV-associated nephropathy . The chemotherapeutic vitamin D analog EB-1089 inhibited this HIV-induced VDR gene downregulation in kidney cells . In our study, EB-1089 did not affect VDR expression during CMV replication despite the use of comparably high concentrations . EB-1089 had no significant effect on CMV replication either. HIV-caused VDR downregulation was reported to be mediated through generation of reactive oxygen species (ROS) . In contrast to HIV, CMV induces expression of antioxidant and detoxifying enzymes to combat ROS . Hence, the mechanisms and functional consequences of VDR gene downregulation are very likely different between HIV and CMV infection explaining the differences in effectiveness of EB-1089 on replication of these two viruses.
The observed upregulation of CYP27B1 and downregulation of CYP24A1 during CMV replication may further indicate a specific viral interference with VDR gene expression. In the present study, CMV replication was associated with a marked and persistent suppression of CYP24A1 expression within 12 hrs p.i. and a gradual and marked upregulation of CYP27B1 expression. These observations may indicate not only a VDR gene downregulation during CMV replication but also an inhibition of the negative feedback loop by a relative deficiency of VDR-associated calcitriol. The relative deficiency in VDR- associated calcitriol could not be antagonized by supplementation of high concentrations of this vitamin D metabolite during CMV replication.
Regulation of VDR, CYP27B1, and CYP24A1 may vary depending on tissue or cell type and differentiation or activation status of the cells evaluated . For example, VDR is expressed in activated but not in resting T-cells [42,43]. Interestingly, CMV infects several different mammalian cells - predominantly monocytes-macrophages, as well as endothelial and epithelial cells. Differentiation of monocytes into macrophages is required for achieving a fully permissive CMV infection . Calcitriol enhances VDR expression of monocytes and macrophages . Hence, the observed downregulation of VDR expression under CMV replication may be rather an ancillary effect of CMV during viral modulation of the cellular machinery to provide suitable host factors for viral replication.
In contrast to the observed downregulation of VDR gene expression during CMV or HIV infection, our observations indicate that downregulation of VDRgene expression is not universally associated with viral infections. To evaluate if other viral pathogens also interfere with the VDR-system, we performed the same gene expression screens on influenza virus or adenovirus-infected cells. VDR gene expression was even upregulated continuously during influenza virus infection. A potential explanation for these different VDR responses to the viral infections evaluated may be based on the innate immune response to intracellular pathogens. Activation of TLRs up-regulates expression of VDR and CYP27B1 followed by induction of the antimicrobial peptide cathelicidin [21,56,57]. Recently, Landais et al. demonstrated that the viral micro-RNA (miRNA) miR-UL112-3p inhibits TLR2 signaling and NFkB activation during CMV infection . Moreover, innate immune responses to HIV infection follow different pathways than responses to CMV or influenza virus infection, which may also explain the differences in the observed response to calcitriol supplementation and EB-1089 treatment in vitro.
In conclusion, we found that vitamin D does not inhibit CMV replication significantly in vitro. Instead, CMV replication rapidly and efficiently downregulated VDR gene expression and modified the expression of the vitamin D system significantly. The interference with VDR expression was specific for CMV and not for other common, human viruses such as adenovirus or influenza viruses. Modifications of this system may have extensive consequences beyond the cellular level. Changes of the vitamin D homeostasis could significantly affect more than 80 pathways linked to cancer, autoimmune disorders, and cardiovascular disease [18,28,59]. Our observations in an in vitro model of CMV infection warrant further in vitro and in vivo evaluations for a comprehensive characterization of the consequences on a global scale
- Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol - April 2021 in VitaminDWiki
- Outbreaks of a Presumed Infectious Agent Associated with Changes in Fertility, Stillbirth, Congenital Abnormalities and the Gender Ratio at Birth - 2017 Free PDF
- Controversial Effects of Vitamin D and Related Genes on Viral Infections, Pathogenesis, and Treatment Outcomes - March 2020. Free PDF
- Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol April 2021 Free PDF
Vitamin D can inhibit enveloped virus (e.g. Corona, Herpes, Zoster, Epstein, Hepatitis, RSV) – March 2011
Examples of enveloped virus: Coronavirus, Herpes simplex virus (cold sore), varicella-zoster virus (Shingles), cytomegalovirus, Epstein-Barr virus, Hepatitis B virus, retrovirus - like HIV, Dengue virus, Yellow fever virus, Measles virus, Mumps virus, smallpox
Vitamin D Receptor is associated in over 40 autoimmune studies
The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019
Vitamin D Receptor activation can be increased by any of: Resveratrol, Omega-3, Magnesium, Zinc, Quercetin, non-daily Vit D, Curcumin, intense exercise, Ginger, Essential oils, etc Note: The founder of VitaminDWiki uses 10 of the 12 known VDR activators
CMV is very common, but most people are unaware of it
CMV 1 in 150 people (vs 75% of adults - above)
- Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cells - Jan 2017 https://doi.org/10.1016/j.jsbmb.2016.08.002 FREE PDF
- Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis - Jan 2011 https://doi.org/10.1177/1352458510394398 FREE PDF
- The Role of Cytomegalovirus (CMV) and Vitamin D in Multiple Sclerosis (MS) - 2020 https://doi.org/10.37506/mlu.v20i1.471 FREE PDF